AI-generated summary
The authors randomized 30 adults with diabetic neuropathy to conventional treatment, intradermic laser irradiation on blood (ILIB) at 660 nm, or a sham device. The ILIB group reported lower pain and better quality of life than the control and sham groups, which the authors describe as effective. The abstract does not describe the sample's characteristics or long-term outcomes.
- Participants
- 30
- Who or what was studied
- Adults with diabetes mellitus and diabetic neuropathy
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract reports a small sample of 30 volunteers and does not describe follow-up duration or how sham blinding was assessed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Power
- 100 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Neuropathy, Laser, Confidence interval. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.